Table 3.

Serotonin 6 and 7 Receptors Antagonist Under Clinical Trial

Compound	Indication	Clinical Trial Phase		Clinical Data and Status	Reference
Idalopirdine	Schizophrenia	Phase II	5-HT6R Antagonist	Well tolerated in both dose ranging and a multi-dose cohort	[93]
ABT-354	Schizophrenia and Alzheimer’s	Phase III	5-HT6R antagonist	Tested in phase I and II clinical trials	[88]
Lu AE58054	Schizophrenia and Alzheimer’s	Phase II	5-HT6R antagonist	The primary outcome measure was efficacy effect of treatment based on the Positive and Negative Syndrome Scale total score	[88,94]
AVN-211	Schizophrenia	Phase II	5-HT6R antagonist	Significant improvement of total Positive and Negative Syndrome in female patients	[95,96]
SYN-114	Schizophrenia and Alzheimer’s	Phase I	5-HT6R antagonist	This product has completed phase I single and multiple ascending dose studies	[88]
PRX-07034	Schizophrenia	Phase II	5-HT6R antagonist	No recent reports of development identified for phase I development	[97]
SGS-518	Schizophrenia	Phase II	5-HT6R antagonist	Safe and well tolerated by patients with cognitive improvement. Terminated because of lack of efficacy	[32]
LY-483,518	Schizophrenia	Phase II	5-HT6R antagonist	No recent reports of development identified for phase II development in schizophrenia	[89,98]
SUVN-502	Schizophrenia	Phase I	5-HT6R antagonist	Satisfactory result and passed for phase II	[65,99]
RP5063 (RP5000)	Schizophrenia	Phase III	5-HT 6 and 7 receptor antagonist	Effective, well tolerated, and 100 mg oral dose is the maximum tolerated dose	[100]
Aripiprazole controlled release	Schizophrenia	Phase I	5-HT7R antagonist	No recent reports of development identified for phase I development in schizophrenia in Europe	[101]